IgG2m4, an engineered antibody isotype with reduced Fc function

mAbs

Volumn 1, Issue 6, 2009, Pages 572-579

  An, Zhiqiang ^a   Forrest, Gail ^a   Moore, Renee ^b   Cukan, Michael ^b   Haytko, Peter ^a   Huang, Lingyi ^a   Vitelli, Salvatore ^a   Zhao, Jing Zhang ^a   Lu, Ping ^a   Hua, Jin ^a   Gibson, Christopher R ^a   Harvey, Barrett R ^a   Montgomery, Donna ^a   Zaller, Dennis ^a   Wang, Fubao ^a   Strohl, William ^a  

^a Department of Biologics Research ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Benign blocker; C1q; Fc receptors; IgG; IgG2m4; Isotype

Indexed keywords

AMINO ACID; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2M4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RECEPTOR BINDING; RHESUS MONKEY; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT C1Q; CRICETINAE; HALF-LIFE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, IGG;

EID: 77953652926     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.6.10185     Document Type: Article

References (41)

1. Maggon K. Monoclonal antibody "Gold Rush". Current Medicinal Chemistry 2007; 14:1978-1987.
2. th Edition 2003 W.H. Freeman and Company, New York.
3. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-23524 (Pubitemid 44274126)
4. Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001; 13:993-1002. (Pubitemid 32750502)
5. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nature Review Immunol 2007; 7:715-725 (Pubitemid 47327396)
6. Clark MR. IgG effector mechanisms. Chem Immunol 1997; 65:88-110.
7. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15:203-234
8. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991; 9:457-492
9. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47.
10. Bindon CI, Hale G, Brüggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168:127-142 (Pubitemid 18195139)
11. Chappel MS, Isenman DE, Everett M, Xu Y-Y, Dorrington KJ, Klein MH. Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point mutated antibodies. Proc Natl Acad Sci 1991; 88:9036-9040 (Pubitemid 21915563)
12. Tao M-H, Canfield SM, Morrison SL. The differential ability of IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991; 173:1025-1028
13. Medgyesi D, Uray K, Sallai K, Hudecz F, Koncz G, Abramson J, et al. Functional mapping of the FcγRII binding site on human IgG1 by synthetic peptides. Eur J Immunol 2004; 34:1127-1135 (Pubitemid 39255992)
14. Brekke OH, Michaelsen TE, Aase A, Sandin RH, Sandlie I. Human IgG isotype-specific amino acid residues affecting complement-medaited cell lysis and phagocytosis. Eur J Immunol 1994; 24:2542-2547 (Pubitemid 24303105)
15. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993; 23:1098-1104 (Pubitemid 23120172)
16. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003; 40:585-593
17. Thommesen JE, Michaelsen TE, Loset GA, Sandlie I, Brekke OH. Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation. Mol Immunol 2000; 37:995-1004.
18. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178-4184 (Pubitemid 30215076)
19. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991; 173:1483-1491
20. Xu Y, Oomen R, Klein MH. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J Biol Chem 1994; 269:3469-3474 (Pubitemid 24237667)
21. An Z. Antibody therapeutics - a mini review. Trends in Bio/Pharmaceuticals Industry 2008; 4:24-29
22. Peeters M, Balfour J, Arnold D. Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 2008; 28:269-281
23. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate. Blood 1999; 93:3678-3684 (Pubitemid 29249814)
24. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002; 105:9-19.
25. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci 2006; 103:4005-4010
26. Mueller JP, Giannoni MA, Hartman SL, Elliott EA, Squinto SP, Mathis LA, et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 1997; 34:441-452
27. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol 2007; 25:1256-1264 (Pubitemid 350076509)
28. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64:700-704 (Pubitemid 351872072)
29. Hougs L, Avejgaard A, Barington T. The first constant-domain (CH1) exon of human IGHG2 is polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n+) allotype in Caucasians. Immunogenetics 2001; 52:242-248 (Pubitemid 32142811)
30. Kim TD, Cho S-E, Yang C-H, Kim J. Analysis of FcγRIII and IgG Fc polymorphism reveals functional and evolutionary implications of protein-protein interaction. J Mol Evol 2001; 53:1-9. (Pubitemid 32523322)
31. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcgamma receptor IIA and Fcgamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89:1274-1281
32. Sanders LA, Feldman RG, Voorhorst-Ogink MM, de Haas M, Rijkers GT, Capel PJ, et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63:73-81.
33. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613-2624
34. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-2527
35. Parren PW, Warmerdam PA, Boeije LC. On the interaction of IgG subclasses with the low affinity Fcgamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90:1537-1546
36. Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors FcγRI and FcγRIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol 2000; 164:5313-5318 (Pubitemid 30305210)
37. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, Morrison SL. The use of severe combined immunodefficiency mice to study the metabolism of human immuoglobulin G. Cancer 1994; 73:794-799 (Pubitemid 24046633)
38. Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. Antineutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible patyhogenic role for the IgG4 subclass. Clin Exp Immunol 2004; 138:183-192 (Pubitemid 39279983)
39. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276:6591-6604 (Pubitemid 37373524)
40. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnol 2006; 24:210-215
41. Kabat EA,Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. U.S. Public Heath Services, National Institutes of Health, 1991 Bethesda MD.